|  |  |  |  |
| --- | --- | --- | --- |
| PRESS RELEASE**NOT FOR DISTRIBUTION BEFORE 8 AM , OCT 9, 2019** |  |  |  |

 **LEO Pharma to highlight data at 28th Congress of
the European Academy of Dermatology (EADV)**

***Data will communicate new and updated findings, including in the treatment of psoriasis, atopic dermatitis and chronic hand eczema***

**BALLERUP, Denmark, Oct. 9, 2019 -** LEO Pharma A/S, a global leader in medical dermatology, today announced that data from company-sponsored, health economic outcome and investigator-initiated studies will be presented at the 28th annual Congress of the European Academy of Dermatology (EADV), Oct. 9-13, in Madrid, Spain. The scope of research continues to evaluate the company’s approved and investigational therapies toward the company’s mission to help people achieve healthy skin.

“Data that LEO Pharma will present at EADV show how we continue to pioneer medical dermatology with the goal to constantly improve what is possible for patients,” said Kim Kjoeller, Executive Vice President, Global Research & Development, LEO Pharma. “We believe significant unmet needs remain for people affected by psoriasis and eczema – both common and debilitating skin diseases with profound effects on the quality of life of people around the world.”

Abstracts are accessible via computers in the EADV Congress e-Poster Hall during congress hours.

Select data include:

**Oral Presentations**

|  |  |  |  |
| --- | --- | --- | --- |
| **Title**  | **Presenter** | **Time** | **Session No.**  |
| **Multistate modeling of time to response in patients with moderate to severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies** | Jens Strodl Andersen (Ballerup, Denmark) | 15:00 – 15:10, Thursday, Oct. 10 | FC04.01 |
| **The Patient Experience of Chronic Hand Eczema: A Conceptual Model** | Julie Hahn-Pedersen (Ballerup, Denmark) | 09:30 – 09:40, Friday, Oct. 11 | OP01.04 |
| **No increased risk of cancer in children using topical tacrolimus for atopic dermatitis: a 10-year prospective cohort study** | Regina Fölster-Holst (Kiel, Germany) | 11:00-11:15, Saturday, Oct. 12 | D3T01.1J (Late breaking news) |
| **Atopic dermatitis disease biomarkers strongly correlate with IL-13 levels, are regulated by IL-13, and are modulated by tralokinumab in vitro** | Katharina Drerup (Kiel, Germany) | 13:15-13:25, Saturday, Oct. 12 | FC07.01 |

 **e-Posters**

|  |  |  |
| --- | --- | --- |
| **Title**  | **Authors** | **Code** |
| **Qualitative research to explore differences in the core signs, symptoms and HRQoL impacts between Chronic Hand Eczema and Atopic Dermatitis based on conceptual models** | Trennery C., Burrows K., Seiding Larsen L., Grant L., I. Silverberg J., Weisshaar E., V. Besito D., Abramovits W., Stalder J., Hahn-Pedersen J., Kragh N., Arbuckle R. (Macclesfield, United Kingdom) | 05:P0220 |
| **Brodalumab is associated with improvements in patient-reported quality of life: A subgroup analysis of patients with psoriasis and concomitant psoriatic arthritis** | Kokolakis G., Shultz Nielsen V., Hansen J., Carrascosa J. | 08:OP03.02 |
| **Brodalumab versus ustekinumab: Complete skin clearance and improvements in quality of life – A subgroup analysis according to lifestyle factors (tobacco and alcohol)** | Kokolakis G., Shultz Nielsen V., Faurby M., Carrascosa J. | 08:P0438 |
| **Brodalumab is associated with high rates of complete skin clearance: A subgroup analysis of****patients with psoriasis and psoriatic arthritis** | Kokolakis G., Shultz Nielsen V., Hansen J., Carrascosa J | 08:P0439 |
| **Efficacy and safety of calcipotriol plus betamethasone diproprionate cutaneous aerosol foam treatment for psoriasis in patients with body surface area 5–15% and Physician’s global****assessment >/=3** | Iversen L., Kurvits M., Marieke Snel-Prentø A., Menter A. (Aarhus, Denmark) | 40:P1587 |
| **PSO-LONG: use of the psoriasis symptom inventory in a Phase 3 trial studying the long-term efficacy and safety of fixed-dose combination calcipotriol 0.005% and betamethasone diproprionate****0.064% foam in patients with psoriasis** | Lebwohl M., Marieke Snel-Prentø A. (New York, United States) | 40:P1625 |
| **Cost per responder of calcipotriol plus betamethasone dipropionate foam versus non-biologic****systemic therapy for moderate to severe plaque psoriasis in four European countries** | Balak D., Gregoriou S., Calzavara-Pinton P., Viola M., Sawyer L., Nyeland M., Becla L. (Ballerup, Denmark) | 40:P1672 |
| **Assessing the quality and coherence of network meta-analyses of biologics in plaque psoriasis:****what does all this evidence synthesis tell us?** | Wright E., Yasmeen N., Malottki K., Sawyer L., Borg E., Schwenke C. (London, United Kingdom) | 40:P1677 |
| **Biologic therapies and apremilast for patients with moderate to severe psoriasis: a systematic review and network meta-analysis of 52-week PASI response** | Yasmeen N., Sawyer L., Malottki K., Levin L., Jemec G., Apol E. (Ballerup, Denmark) | 40:P1695 |
| **Efficacy and safety of calcipotriol plus betamethasone dipropionate cutaneous foam in treating****scalp psoriasis: a review of data from two phase 2 studies** | Petersen B., Lebwohl M. (New York, United States) | 40:P1732 |
| **Early Improvements in Plaque Psoriasis Clinical Response with Fixed-Combination Calcipotriene and****Betamethasone Dipropionate (Cal/BD) Foam Treatment from the PSO-FAST Trial** | Veverka K., Hansen J., Patel D., Soung J., Stein Gold L. (Madison, United States) | 40:P1773 |
| **Results from a long-term, observational, non-interventional, prospective study in patients with****body psoriasis based on patient-reported outcomes and physician’s assessments (BODYGUARD)** | Bakulev A., Petrunin D. | 40:P1788 |

|  |
| --- |
|  |

Find additional congress information at [eadvmadrid2019.org/](https://eadvmadrid2019.org/). For more information about LEO Pharma, visit [www.leo-pharma.com](http://www.leo-pharma.com).

**NOTES TO EDITORS**

**About psoriasis**

An estimated 125 million people worldwide live with psoriasis.[[1]](#endnote-2) It is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin.[[2]](#endnote-3) The most frequently reported symptoms include thickening and scaling of the skin, itching and erythema (superficial reddening of the skin, usually in patches).2

Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person’s life.2 People with psoriasis, especially those with more severe symptoms, are also at increased risk of developing other serious associated conditions,[[3]](#endnote-4) including heart disease[[4]](#endnote-5),[[5]](#endnote-6),[[6]](#endnote-7) and metabolic diseases (a combination of diabetes, high blood pressure and obesity).[[7]](#endnote-8) Mental health complications, such as depression and anxiety, are also more common in people with psoriasis.[[8]](#endnote-9) According to the World Health Organization, the burden of living with psoriasis is underestimated and it urges for action to fight stigma and improve treatment.2

**About atopic dermatitis**Atopic dermatitis (AD) is a common type of eczema that affects up to 5% of adults across the United States, Canada, Europe and Japan.[[9]](#endnote-10) It is a chronic, relapsing skin disease, characterized by severe itch, dry skin, persistent immune-mediated inflammation, and skin barrier defects.[[10]](#endnote-11)

AD has a significant, negative impact on patients’ well-being, primarily due to the intense itch which leads to disrupted sleep and other negative consequences.10 Patients with uncontrolled, moderate-to-severe AD are often treated with non-targeted, oral systemic therapies, but these have varying degrees of efficacy and are associated with side-effect profiles and monitoring requirements that limit them to short-term use.[[11]](#endnote-12),[[12]](#endnote-13),[[13]](#endnote-14)
**About chronic hand eczema**

Hand eczema (HE) is a heterogeneous disease with many different causes, and ranges in severity from very mild to severe. Clinically, HE is characterized by lesioned skin on the hands that may be red, patchy, swollen, scaly, cracked, or thickened, with symptoms of itch and pain. HE is considered chronic (CHE) when it lasts for more than three months or relapses twice or more per year. Painful fissures and blisters affect a person’s daily life and well-being, and can prevent manual labor, leading to significant economic loss to both individuals and society.[[14]](#endnote-15),[[15]](#endnote-16)

**About LEO Pharma**

LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.

**Contacts:**

Henrik Kyndlev

Global External Communications

+45 3140 6180

hdtdk@leo-pharma.com

Kimberly Whitefield

Global Product Communications, Eczema

+1 862 345 0643

kqwus@leo-pharma.com

###

1. The International Federation of Psoriasis Associations. Available at: https://ifpa-pso.com/ (Accessed March 2019). [↑](#endnote-ref-2)
2. World Health Organization (WHO). Global Report on Psoriasis. Available at: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189\_eng.pdf (Accessed March 2019). [↑](#endnote-ref-3)
3. Reich K. Eur Acad Dermatol Venereol 2012;26(2):3–11. [↑](#endnote-ref-4)
4. Gelfand JM, et al. JAMA 2016;296:1735–41. [↑](#endnote-ref-5)
5. Ahlehoff O, et al. Eur Heart J 2012;33:2054–64. [↑](#endnote-ref-6)
6. Lowes MA, et al. Ann Rev Immunol 2014;32:227–35. [↑](#endnote-ref-7)
7. Langan SM, et al. J Invest Dermatol 2012;132(3 Pt 1):556–562. [↑](#endnote-ref-8)
8. Dalgard F, et al. JID 2015;135(4):984 –991. [↑](#endnote-ref-9)
9. Barbarot S, Auziere S et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi: 10.1111/all.13401. [↑](#endnote-ref-10)
10. Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016; 387:1109-22. [↑](#endnote-ref-11)
11. Boguniewicz M et al. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol 2018;120:10-22. [↑](#endnote-ref-12)
12. Boguniewicz M et al. Expert Perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract 2017;5:1519-1531. [↑](#endnote-ref-13)
13. Johnson B et al. Treatment-resistant atopic dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2019;12:181–192. [↑](#endnote-ref-14)
14. Diepgen TL, Andersen K, Chosidow O, Coenraads PJ, Elsner P, English J, Fartasch M, Gimenez-Arnau A, Nixon R, Sasseville D, Agner T. Guidelines for diagnosis, prevention and treatment of hand eczema - short version. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2015; 13(1): 77-84. [↑](#endnote-ref-15)
15. Diepgen TL, Agner T, Aberer W, Berth-Jones J, Cambazard F, Elsner P, McFadden J, Coenraads PJ. Management of chronic hand eczema. Contact Dermatitis. 2007; 57: 203-210. [↑](#endnote-ref-16)